CLCS Company Profile and Key Details

Q: Who are the executives of CLCS?

Dr. Dennis M. Brown B.Sc., M.A., Ph.D.Co-Founder & Chief Scientific OfficerMr. Itamar ShimratChief Executive Officer, Pres & Chief Financial Officer

PNK : CLCS

Cell Source

$0.00

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Price Chart

Stock Price Today

Cell Source, Inc. (CLCS) stock declined over -33.82%, trading at $0.45 on OTC, down from the previous close of $0.68. The stock opened at $0.45, fluctuating between $0.45 and $0.45 in the recent session.

Stock Snapshot

0.68

Prev. Close

30.58M

Market Cap

0.45

Day Low

-3.51

P/E Ratio

-0.12814

EPS (TTM)

-0.06

Cash Flow per Share

0.45

Open

67.95M

Number of Shares

0.45

Day High

63.92%

Free Float in %

-0.42

Book Value

2.5K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 10, 2026	0.45	0.45	0.45	0.45	9.47K
Sep 09, 2026	0.52	0.55	0.50	0.50	12.14K
Sep 08, 2026	0.57	0.68	0.57	0.68	1.2K
Sep 04, 2026	0.52	0.52	0.52	0.52	5K
Sep 03, 2026	0.74	0.74	0.74	0.74	600
Aug 31, 2026	0.60	0.89	0.57	0.89	4.7K
Aug 27, 2026	0.54	0.58	0.54	0.58	3.92K
Aug 24, 2026	0.55	0.55	0.53	0.53	5.5K
Aug 21, 2026	0.58	0.65	0.51	0.58	4.3K
Aug 20, 2026	0.55	0.58	0.55	0.58	300
Aug 17, 2026	0.60	0.65	0.60	0.65	1.7K
Aug 14, 2026	0.60	0.60	0.51	0.60	5.51K
Aug 13, 2026	0.57	0.61	0.50	0.61	3.06K
Aug 12, 2026	0.57	0.59	0.31	0.56	25.99K
Aug 05, 2026	0.57	0.82	0.57	0.82	3.2K
Aug 04, 2026	0.89	0.89	0.89	0.89	520
Jul 31, 2026	0.57	0.89	0.57	0.89	250
Jul 29, 2026	0.70	0.85	0.70	0.85	1.2K
Jul 28, 2026	0.57	0.82	0.57	0.82	300
Jul 27, 2026	0.84	0.84	0.84	0.84	200

Contact Details

New York City, NY 10019

United States

https://www.cell-source.com 646 416 7896

About Company

Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds application in numerous areas, including enhancing the acceptance of stem cell transplants for conditions like lymphoma, leukemia, and multiple myeloma. Furthermore, it is utilized in treating end-stage kidney disease, various other non-malignant organ diseases, and a spectrum of both cancerous and non-malignant illnesses. Founded in 2012, Cell Source, Inc. maintains its corporate headquarters in New York, New York.

Stock Peers

LZAGF

-5-0.92%

Lonza Group AG$541.00 GNMSF

Genmab A/S$268.61 CMXHF

CSL Limited$192.00 CSLLY

0.75+0.79%

CSL Limited$95.35 UCBJY

-0.06-0.08%

UCB SA$73.15 LZAGY

-0.33-0.61%

Lonza Group AG$53.87 PHMMF

4.3+16.01%

Pharma Mar, S.A.$31.15 BVNKF

Bavarian Nordic A/S$21.20 GRTX

1.53+9.80%

Galera Therapeutics, Inc.$17.15 NURPF

Neuren Pharmaceuticals Limited$14.00

Company Overview

Cell Source, Inc. (OTC:CLCS) closed at $0.45 USD, losing -$0.23 (-33.82%) from the previous close of $0.68. The stock is currently mid-range between its 52-week high and low $0.25 and $2.25. With a market capitalization of about $30.58 million, Cell Source, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-157.98). Key stats such as the average daily volume over the past year has been around 2.80 thousand shares, in line with its 52-week average. Headquartered in New York City, NY, Cell Source, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Itamar Shimrat, the company employs approximately 1 people and listed since May 01, 2014. Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance.

Technical Performance

Average 10-day trading volume of 5.52 thousand shares is slightly above the 3-month average of 3.93 thousand, indicating heightened recent market interest.

Valuation Metrics

Cell Source, Inc. trades at a P/E ratio of -4.5, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -1.09 indicating negative book value, which may reflect financial stress. The P/FCF stands at -11.19, also below market averages.

Dividend & Fair Value

Cell Source, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.23. This means the shares are trading below this model’s fair value.

Financial & Profitability Overview

Over the trailing twelve months, Cell Source has not generated any revenue. Returns are negative, with ROA at -1260.90% and ROE at 40.90%.
On valuation metrics, Cell Source trades at a P/E of -4.50, P/S of 0.00 and P/B of -1.09. Liquidity is tight, with a current ratio of 0.02 and quick ratio of 0.02. Debt-to-equity is -0.58, supported by a cash flow-to-debt ratio of -0.21.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2022, Cell Source posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Operating income was - $4.18M (margin 0.0%). Net income was- $5.17M (EPS - $0.15).
The company ended the quarter with $222.67K in cash and short-term investments, a total debt of $7.90M, and net debt of $7.68M. Total assets were $409.85K, with equity of - $12.63M. Financials further reflected weakness, with operating cash flow of - $3.14M, free cash flow of - $3.14M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Cell Source, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Key Takeaways

Valuation shows Cell Source, Inc. trading at a premium to the broader market with a P/E of -4.5.

Frequently Asked Questions

What is the current Cell Source, Inc. (CLCS) stock price?

Cell Source, Inc. (OTC: CLCS) stock price is $0.45 in the last trading session. During the trading session, CLCS stock reached the peak price of $0.45 while $0.45 was the lowest point it dropped to. The percentage change in CLCS stock occurred in the recent session was -33.82% while the dollar amount for the price change in CLCS stock was - $0.23.

CLCS's industry and sector of operation?

The OTC listed CLCS is part of Biotechnology industry that operates in the broader Healthcare sector. Cell Source, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CLCS?

Dr. Dennis M. Brown B.Sc., M.A., Ph.D.
Co-Founder & Chief Scientific Officer
Mr. Itamar Shimrat
Chief Executive Officer, Pres & Chief Financial Officer

How CLCS did perform over past 52-week?

CLCS's closing price is 300% higher than its 52-week low of $0.25 where as its distance from 52-week high of $2.25 is -99.89%.

How many employees does CLCS have?

Number of CLCS employees currently stands at 1.

Link for CLCS official website?

Official Website of CLCS is: https://www.cell-source.com

How do I contact CLCS?

CLCS could be contacted at phone 646 416 7896 and can also be accessed through its website. CLCS operates from 57 West 57th Street, New York City, NY 10019, United States.

How many shares of CLCS are traded daily?

CLCS stock volume for the day was 2.5K shares. The average number of CLCS shares traded daily for last 3 months was 2.8K.

What is the market cap of CLCS currently?

The market value of CLCS currently stands at $30.58M with its latest stock price at $0.45 and 67.95M of its shares outstanding.

Employees	1
Beta	-157.98
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

CLCS Company Profile and Key Details

Cell Source

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Company Overview

Dividend & Fair Value

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Valuation Metrics